<DOC>
	<DOCNO>NCT02023359</DOCNO>
	<brief_summary>An observational study patient advance ER+ , HER2 negative breast cancer , treat everolimus exemestane combination . The objective study assess safety pattern everolimus real world setting .</brief_summary>
	<brief_title>Danish Observational Study Everolimus Plus Exemestane Hormone Receptor ( HR ) Positive , Human Epidermal Growth Factor 2 ( HER2 ) - Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Postmenopausal woman HRpositive , HER2negative advance breast cancer treat everolimus exemestane accord approved Summary Product Characteristics ( SmPC ) . Patients start treatment approval indication initiation study retrospectively include , provide systematically assessed adverse event . The decision treat patient everolimus exemestane must independent patient 's participation study . The patient must provide sign Informed Consent data capture . No formal exclusion criterion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Advanced breast cancer</keyword>
	<keyword>Everolimus</keyword>
</DOC>